Molecular targets for breast cancer therapy and prevention

Related Experiment Videos

J Bange1, E Zwick, A Ullrich

  • 1Max-Planck-Institut of Biochemistry, Department of Molecular Biology Martinsried, Germany.

Nature Medicine
|May 1, 2001
PubMed

Insights

Gene-based research following the human genome sequence has yielded new breast cancer therapies. These advancements, developed over 20 years, are now available for clinical testing and treatment.

Area of Science:

  • Genomics and Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The completion of the human genome sequence has accelerated the identification of genes implicated in breast cancer.
  • Understanding the genetic basis of breast cancer is crucial for developing targeted therapies.

Purpose of the Study:

  • To review gene-based breast cancer therapies developed over the past two decades.
  • To highlight therapies approved for clinical testing or treatment.

Main Methods:

  • Literature review of gene-based research in breast cancer.
  • Analysis of therapies emerging from genomic studies.
  • Compilation of approved clinical trials and treatments.

Main Results:

  • Several novel breast cancer therapies have arisen from gene-based research.
  • These therapies target specific genetic alterations involved in breast cancer.
  • A significant number of these therapies have reached clinical validation.

Conclusions:

  • Gene-based scientific efforts have significantly advanced breast cancer treatment options.
  • The human genome sequence has been instrumental in discovering targeted therapies.
  • Continued genomic research promises further breakthroughs in breast cancer care.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...